Axsome Therapeutics,Inc. (NASDAQ:AXSM) Files An 8-K Other Events
Item 8.01. Other Events.
On January7, 2019, Axsome Therapeutics,Inc. (the “Company”) issued a press release giving an update regarding shares sold under the Company’s previously announced at-the-market (“ATM”) facility.
The full text of the press release is filed as Exhibit99.1 hereto and is incorporated herein by reference.
Sales of the shares of common stock in the ATM offering are made to a prospectus supplement to the Company’s previously filed and currently effective Registration Statement on FormS-3 (File No.333-214859). This Current Report on Form8-K shall not constitute an offer to sell or the solicitation of an offer to buy the securities discussed herein, nor shall there by any offer, solicitation or sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Item 9.01. Financial Statements and Exhibits.
(d)Exhibits.
|
Exhibit Number |
Description |
|
99.1 |
Press release dated January7, 2019. |
Axsome Therapeutics, Inc. Exhibit
EX-99.1 2 a19-2090_1ex99d1.htm EX-99.1 Exhibit 99.1 Axsome Therapeutics Raises $23.3 Million Under Existing ATM Facility NEW YORK,…
To view the full exhibit click here
About Axsome Therapeutics,Inc. (NASDAQ:AXSM)
Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain. It is developing AXS 02 for the treatment of pain in over three conditions, such as complex regional pain syndrome (CRPS); knee osteoarthritis (OA) associated with bone marrow lesions (BMLs), and chronic low back pain (CLBP), associated with type I, or mixed type I and type II Modic changes (MCs). Its product candidate, AXS 05, is a fixed dose combination of dextromethorphan (DM) and bupropion. It is developing AXS 05 for the treatment of over two conditions, such as treatment resistant depression (TRD), and agitation in patients with Alzheimer’s disease (AD).